Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 85 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR What Caregivers Should Know About End-of-Life Care Issues for People With... September 8, 2022 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 EMA Recommends Extension of Therapeutic Indications for Osimertinib April 26, 2021 FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 Load more HOT NEWS Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected... Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs
